Results from the TRIUMPH-1 Phase 3 trial show participants on 9mg losing an average of 23.7% of body weight, and those on 12mg losing 25% at 80 weeks overall with the subgroup of participants escalated to maximum tolerated dose achieving the full 28.3% Synedica Retatrutide weight loss result
Its preclinical profile is genuinely remarkable: angiogenesis stimulation, tendon healing, and gastrointestinal protection in rodent models
Well, now that we have all this background, lets talk about our most recent co-authored report, which again, is a joint effort between IQVIA Institute for Human Data Science and GHLF
Understanding this reality helps set realistic expectations: semaglutide works exceptionally well while you take it, but stopping the medication generally means returning to previous eating patterns and weight trends unless significant lifestyle changes have been established
Could dosages be reduced while maintaining benefits
K.BoweS